Skip to main content
Top
Published in: Reactions Weekly 1/2023

01-06-2023 | Rubella | Case report

Measles-mumps-and-rubella-virus-vaccine

Respiratory tract infection and maculopapular rash: 2 case reports

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Desjardins M, et al. Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant. Open Forum Infectious Diseases 8: No. 12, Dec 2021. Available from: URL: https://academic.oup.com/ofid Desjardins M, et al. Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant. Open Forum Infectious Diseases 8: No. 12, Dec 2021. Available from: URL: https://​academic.​oup.​com/​ofid
Metadata
Title
Measles-mumps-and-rubella-virus-vaccine
Respiratory tract infection and maculopapular rash: 2 case reports
Publication date
01-06-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41096-x

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Multiple drugs

Case report

Pamidronic-acid

Case report

Antineoplastics

Case report

Sulphan-blue